Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Rao, G. G.
Right arrow Articles by Tobin, C. M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Rao, G. G.
Right arrow Articles by Tobin, C. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2001) 48, 931-932
© 2001 The British Society for Antimicrobial Chemotherapy

Correspondence

Linezolid levels in pancreatic secretions

G. Gopal Raoa,*, A. Stegera and C. M. Tobinb

a Departments of Microbiology and Surgery, University Hospital Lewisham, London SE13 6LH; b Bristol Centre for Antimicrobial Research and Evaluation, Southmead Hospital, Bristol BS10 5NB, UK

Sir,

Linezolid is the first of a novel class of antimicrobial agents, the oxazolidinones, and is effective against a broad range of Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci.1

Following parenteral or oral . . . [Full Text of this Article]

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?